Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists

Published:2023-01-18 Issue:2 Volume:14 Page:191-198
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Schnute Mark E.¹^ORCID,Trujillo John I.²^ORCID,Lee Katherine L.¹^ORCID,Unwalla Ray¹,Vajdos Felix F.²,Kauppi Björn³^ORCID,Nuhant Philippe²,Flick Andrew C.²,Crouse Kimberly K.⁴,Zhao Yajuan⁴,Samuel Amanda⁵,Lombardo Vincent²,Taylor Alexandria P.²,Brault Amy L.²,Knafels John D.²,Vazquez Michael L.¹,Berstein Gabriel⁴

Affiliation:

1. Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States

2. Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States

3. Karo Pharma AB, 111 48 Stockholm, Sweden

4. Inflammation and Immunology Research, Pfizer Inc., Cambridge, Massachusetts 02139, United States

5. Drug Product Design, Pfizer Inc., San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00500

Reference27 articles.

1. The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells

2. Interleukin 17 is a chief orchestrator of immunity

3. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

5. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrocyclization strategy for improving candidate profiles in medicinal chemistry;European Journal of Medicinal Chemistry;2024-06

2. Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases;Journal of Pharmaceutical Analysis;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3